Ulenistamab

尤尼妥单抗

Report date: 2024/06/27 11:03:46

Base Information

Drug NameUlenistamab
Drug Alias NameAnti-PAUF antibody (Prestige Biopharma)PBP-1510
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionPancreatic adenocarcinoma upregulated factor inhibitors
TargetsPancreatic adenocarcinoma upregulated factor
Therapy Area/IndicationsPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingaporeAustralia +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesPrestige BioPharma Ltd
China Registration ClassN/A

Develop Information

Active CompaniesPrestige BioPharma Ltd
Inactive CompaniesN/A
Active IndicationsPancreatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A